UA98666C2 - Лекарственный препарат на основе щавелевой кислоты, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения - Google Patents
Лекарственный препарат на основе щавелевой кислоты, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ леченияInfo
- Publication number
- UA98666C2 UA98666C2 UAA201003471A UAA201003471A UA98666C2 UA 98666 C2 UA98666 C2 UA 98666C2 UA A201003471 A UAA201003471 A UA A201003471A UA A201003471 A UAA201003471 A UA A201003471A UA 98666 C2 UA98666 C2 UA 98666C2
- Authority
- UA
- Ukraine
- Prior art keywords
- oxalic acid
- medicinal preparation
- treatment method
- malignant cells
- action against
- Prior art date
Links
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 title abstract 6
- 238000000034 method Methods 0.000 title abstract 2
- 235000006408 oxalic acid Nutrition 0.000 title abstract 2
- 230000000118 anti-neoplastic effect Effects 0.000 title 1
- 230000001747 exhibiting effect Effects 0.000 title 1
- 230000003211 malignant effect Effects 0.000 title 1
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 abstract 2
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229960002949 fluorouracil Drugs 0.000 abstract 1
- 230000000771 oncological effect Effects 0.000 abstract 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 abstract 1
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Изобретение относится к медицине, в частности к средствам лечения онкологических заболеваний, касается лекарственного препарата, содержащего щавелевую кислоту, литий хлористый и дополнительно содержащего диметилксантин, фторурацил и кислый сернокислый натрий.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAA201003471A UA98666C2 (ru) | 2010-03-25 | 2010-03-25 | Лекарственный препарат на основе щавелевой кислоты, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения |
| PCT/UA2010/000015 WO2011119126A1 (ru) | 2010-03-25 | 2010-03-26 | Применение щавелевой кислоты в производстве лечебного препарата противоопухолевого действия по отношению к злокачественным клеткам, лечебный препарат на его основе и способ лечения |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| UAA201003471A UA98666C2 (ru) | 2010-03-25 | 2010-03-25 | Лекарственный препарат на основе щавелевой кислоты, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA98666C2 true UA98666C2 (ru) | 2012-06-11 |
Family
ID=44673473
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA201003471A UA98666C2 (ru) | 2010-03-25 | 2010-03-25 | Лекарственный препарат на основе щавелевой кислоты, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения |
Country Status (2)
| Country | Link |
|---|---|
| UA (1) | UA98666C2 (ru) |
| WO (1) | WO2011119126A1 (ru) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013074055A1 (ru) * | 2011-11-16 | 2013-05-23 | ШИМАНСКИЙ, Аркадий Петрович | Способ оздоровления и омоложения организма человека и фармацевтическая композиция для его осуществления |
| RU2712443C1 (ru) * | 2018-12-14 | 2020-01-29 | Федеральное государственное бюджетное учреждение науки институт химии растворов им. Г.А. Крестова Российской академии наук | Сокристаллическая форма 1-[5-(4-хлорфениламино)-1,2,4-тиадиазол-3-ил]-пропан-2-ола |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6133317A (en) * | 1995-11-15 | 2000-10-17 | Hart; Francis J. | Oxalic acid or oxalate composition and method of treatment |
| AU2003270202A1 (en) * | 2002-09-17 | 2004-04-08 | Centre National De La Recherche Scientifique | Pharmaceutical compositions increasing camp useful for the treatment of cancers |
| JP2008501650A (ja) * | 2004-06-03 | 2008-01-24 | エフ.ホフマン−ラ ロシュ アーゲー | オキサリプラチンおよびegfr阻害剤を用いた処置 |
| ZA200701578B (en) * | 2004-07-23 | 2008-09-25 | Om Pharma | Combination anticancer therapy and pharmaceutical compositions therefore |
| CN101657203B (zh) * | 2007-03-02 | 2012-09-05 | 卧龙岗大学 | 抗癌药的组合物及递送方法 |
-
2010
- 2010-03-25 UA UAA201003471A patent/UA98666C2/ru unknown
- 2010-03-26 WO PCT/UA2010/000015 patent/WO2011119126A1/ru not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011119126A1 (ru) | 2011-09-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX364229B (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
| PH12015501344A1 (en) | Zinc amino acid halide complex with cysteine | |
| AU2011328009A8 (en) | Compounds and methods for treating pain | |
| GB201106743D0 (en) | Novel compounds | |
| WO2012129341A3 (en) | Disease detection in plants | |
| PL3321355T3 (pl) | Sposoby i kompozycje do klinicznego pozyskiwania komórek alogenicznych oraz zastosowania terapeutyczne | |
| MX2015017036A (es) | Metodo para producir celulas progenitoras renales y farmaco que comprende las mismas. | |
| EP2626071A4 (en) | APPLICATIONS OF ARCTIGENIN FOR THE FORMULATION OF MEDICAMENTS FOR THE PROPHYLAXIS OR THE TREATMENT OF DISEASES RELATED TO THE REDUCTION OF RED BLOOD BODIES | |
| EP2672970A2 (en) | Forms of rifaximin and uses thereof | |
| WO2013022740A3 (en) | Gpr35 ligands and the uses thereof | |
| MX364220B (es) | Metodos de tratamientos de fibrosis. | |
| HUE057439T2 (hu) | Terápiás vakcina 1-es típusú cukorbetegség kezelésére gyermekekben, sejtválogató alkalmazása és eljárás TREG sejtek sokszorosítására 1-es típusú cukorbetegség kezelésére szolgáló terápiás vakcina elõállítására | |
| WO2012048330A3 (en) | Treatment of motor neuron disease | |
| CA2837895C (en) | Methods of treating or preventing neurological diseases | |
| WO2011107866A3 (en) | Silyl-derivatives of polysaccharides | |
| SG195170A1 (en) | Methods of treating or preventing rheumatic disease | |
| UA98666C2 (ru) | Лекарственный препарат на основе щавелевой кислоты, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения | |
| EP2568990A4 (en) | METHOD OF PRODUCING PLEURODESIS | |
| MX2013012551A (es) | Uso de sales de 3-carboxi-n-etil-n,n-dimetilpropan-1-aminio en el tratamiento de enfermedades cardiovasculares. | |
| EP2886548A4 (en) | PROCESS FOR THE PREPARATION OF A BORINIC ACID DERIVATIVE AND NEW BORIC ACID DERIVATIVE | |
| UA98665C2 (ru) | Лекарственный препарат, проявляющий противоопухолевое действие в отношении злокачественных клеток, и способ лечения | |
| IL234087A0 (en) | The composition of an ascorbic acid derivative and a method for its production, a solution of an ascorbic acid derivative and an external preparation for the skin | |
| UA69928U (ru) | Способ моделирования повреждения генома эпителиоцитов слизистой оболочки полости рта | |
| HK1196602A1 (zh) | 作為離子通道調節劑的稠合雜環化合物 | |
| UA100317C2 (ru) | Способ определения физиологического состояния организма человека |